See more : Toei Animation Co.,Ltd. (TOEAF) Income Statement Analysis – Financial Results
Complete financial analysis of Olema Pharmaceuticals, Inc. (OLMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olema Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sambandam Spinning Mills Limited (SAMBANDAM.BO) Income Statement Analysis – Financial Results
- Alpha Capital Acquisition Company (ASPCW) Income Statement Analysis – Financial Results
- Selkirk Group Plc (SELK.L) Income Statement Analysis – Financial Results
- O.A.T., Inc. (OATN) Income Statement Analysis – Financial Results
- Aiful Corporation (AIFLF) Income Statement Analysis – Financial Results
Olema Pharmaceuticals, Inc. (OLMA)
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| Gross Profit | -377.00K | -1.66M | -1.66M | -11.00K | -9.03K | -8.24K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.14M | 82.27M | 51.10M | 13.70M | 3.92M | 1.69M |
| General & Administrative | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Other Expenses | 0.00 | -27.00K | -47.00K | 0.00 | 0.00 | -31.00K |
| Operating Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Cost & Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Interest Income | 8.32M | 2.23M | 442.00K | 60.00K | 7.00K | 4.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 653.00K | 0.00 | 28.00K |
| Depreciation & Amortization | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| EBITDA | -104.58M | -103.13M | -69.43M | -21.52M | -4.31M | -2.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.96M | -106.99M | -71.49M | -21.53M | -4.32M | -2.08M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.31M | 2.20M | 395.00K | -593.00K | 7.00K | -118.00K |
| Income Before Tax | -96.66M | -104.79M | -71.10M | -22.12M | -4.32M | -2.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.20M | -210.00K | 642.00K | -155.86K | -90.00K |
| Net Income | -96.66M | -102.59M | -70.89M | -22.76M | -4.32M | -2.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| EPS Diluted | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| Weighted Avg Shares Out | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
| Weighted Avg Shares Out (Dil) | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
Olema: Two-Pronged Approach To Treat Breast Cancer Patients
Initiation of the pivotal OPERA-01 study, using palazestrant for the treatment of 2nd-line/3rd-line HR+/HER2- metastatic breast cancer patients, expected in Q4 of 2023. Monotherapy results from the phase 2 study, using palazestrant for the treatment of 2nd-line/3rd-line HR+/HER2- metastatic breast...
What Makes Olema Pharmaceuticals, Inc. (OLMA) a New Buy Stock
Olema Pharmaceuticals, Inc. (OLMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 91.97% Upside in Olema Pharmaceuticals, Inc. (OLMA): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 92% in Olema Pharmaceuticals, Inc. (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
What Makes Olema Pharmaceuticals, Inc. (OLMA) a Good Fit for 'Trend Investing'
Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price...
The 7 Best Small-Cap Stocks to Buy Now: September 2023
While the rule of thumb in the market is to invest in stable enterprises in industries with which you're familiar, sometimes you need to hit the gas with the best small-cap stocks to buy. Let me give you a real-world...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will present...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Olema Oncology Announces Combined Financing for Up to $180 Million
$130 million equity private placement led by Paradigm BioCapital with participation by Lightspeed Venture Partners, Deep Track Capital, BVF Partners L.P., Cormorant Asset Management, Vivo Capital, Logos Capital, and Woodline Partners LP
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SAN FRANCISCO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today reported financial results for the second...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Source: https://incomestatements.info
Category: Stock Reports